A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis

NCT ID: NCT01585233

Last Updated: 2025-11-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-04-30
• Study Completion Date: 2015-01-07

Brief Summary

The purpose of this study is to explore the safety and tolerability of multiple doses of ASKP1240 compared to placebo and determine Pharmacokinetics and Pharmacodynamics in subjects with moderate to severe psoriasis.

Detailed Description

Treatment with ASKP1240 or placebo will be over 4 weeks (Baseline/Day 1, Days 15 and Day 29) with 12 weeks of follow-up for a total of 16 weeks.

Conditions

Psoriasis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Cohort 1

ASKP1240 lowest dose

Group Type: EXPERIMENTAL

ASKP1240

Intervention Type: DRUG

Intravenous

Cohort 2

ASKP1240 low dose

Group Type: EXPERIMENTAL

ASKP1240

Intervention Type: DRUG

Intravenous

Cohort 3

ASKP1240 high dose

Group Type: EXPERIMENTAL

ASKP1240

Intervention Type: DRUG

Intravenous

Cohort 4

ASKP1240 highest dose

Group Type: EXPERIMENTAL

ASKP1240

Intervention Type: DRUG

Intravenous

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Intravenous

Interventions

ASKP1240

Intravenous

Intervention Type: DRUG

Placebo

Intravenous

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subject has a clinical diagnosis of moderate to severe plaque psoriasis for 6 months or longer with at least 5% or greater Body Surface Area (BSA) affected with plaque psoriasis
• Subject must be a candidate for phototherapy and/or systemic therapy
• Subject must agree to avoid prolonged exposure to the sun and avoid the use of tanning booths or other ultraviolet light sources during the study
• Female subject must be either:

• post-menopausal (defined as at least 1 year without any menses) prior to Screening, or
• premenarchal prior to Screening, or
• documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening), or
• if of childbearing potential, must have a negative serum pregnancy test at Screening and if sexually active must be using highly effective contraception. All sexually active subjects will be required to use highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and throughout the study period and for 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.
• Female subject must not be lactating and must not be breastfeeding at Screening or during the study period and for 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.
• Female subject must not donate ova starting at Screening and throughout the study period and for 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.
• Male subject and their female spouse/partners who are sexually active must be using highly effective contraception1 consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continue throughout the study period and for 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.
• Male subject must not donate sperm starting at Screening and throughout the study period and for at least 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.
• Highly effective contraception is defined as:

• Established use of oral, injected or implanted hormonal methods of contraception.
• Placement of an intrauterine device (IUD) or intrauterine system (IUS)
• Barrier methods of contraception: Condom alone or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
• Subject must be willing and able to comply with the study requirements, including prohibited concomitant medication restrictions.

Exclusion Criteria

• Subject has non-plaque psoriasis (such as guttate, erythrodermic or pustular psoriasis)
• Subject has received treatment with systemic, non-biologic psoriasis therapy or other systemic immunosuppressant including investigational use of an approved agent within the last 30 days or 5 half-lives, whichever is longer, prior to the first dose of study drug
• Subject has ever been treated with efalizumab (Raptiva®)
• Subject has a total B lymphocyte count by flow cytometric determination that is less than the lower limit of normal
• Subject has a hemoglobin, that are below the lower limit
• Subject has a total white count, total lymphocyte count, total neutrophil count or total platelet that are below the lower limit
• Subject has any of the following lab values:

• ALT ≥ 1.5 x upper limit of normal
• AST ≥ 1.5 x upper limit of normal
• Total bilirubin ≥ 1.5 x upper limit of normal
• Subject has previously received ASKP1240 or has participated in a study involving ASKP1240
• Subject has > 45 body mass index (BMI)
• Subject with a positive Tubercle Bacillus (TB) test who has not previously received adequate antimicrobial therapy for TB or is currently on, or is planned to start TB antimicrobial therapy
• Subject has abnormal chest x-ray indicative of acute or chronic lung disease
• Subject has uncontrolled intercurrent illness, including, but not limited to ongoing or active infection, any clinically significant cardiac disease seizure disorder, or psychiatric illness/social situations that would limit compliance with study requirements
• Subject has a history of any malignancy regardless of the location and the time of diagnosis in the last 5 years (including in-situ carcinoma of the cervix, but excluding successfully treated non-metastatic basal cell and squamous cell carcinoma)
• Subject has received live or live attenuated virus vaccinations within the last 30 days prior to first dose of study drug
• Subject has received treatment with another investigational drug within 30 days or 5 half-lives; whichever is longer, prior to the initiation of Screening
• Subject has a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody
• Subject has a history of a positive test for human immunodeficiency virus (HIV) infection
• Subject has received treatment with systemic, biologic psoriasis therapy or other systemic immunosuppressant including investigational use of an approved agent within the last 56 days or 5 half-lives whichever is longer, prior to the first dose of study drug

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kyowa Kirin Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Astellas Pharma Global Development, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Senior Medical Director

Role: STUDY_DIRECTOR

Astellas Pharma Global Development

Locations

Specialist Connect

Brisbane, Queensland, Australia

CMAX

Adelaide, Victoria, Australia

Epworth Hospital

Richmond, Victoria, Australia

Linear Research

Nedlands, Western Australia, Australia

Durondel C.P. Inc, The Dermatology Clinic

Moncton, New Brunswick, Canada

New Lab Clinical Research

St. John's, Newfoundland and Labrador, Canada

Ultranova Skincare

Barrie, Ontario, Canada

K. Papp Clinical Research

Waterloo, Ontario, Canada

Innovaderm Research, Inc.

Montreal, Quebec, Canada

Auckland Clinical Studies

Auckland, , New Zealand

Christchurch Clincial Studies Trust, Ltd.

Christchurch, , New Zealand

P3 Research, Tauranga

Tauranga, , New Zealand

P3 Research, Wellington

Wellington, , New Zealand

Countries

Australia; Canada; New Zealand

Related Links

https://www.trialsummaries.com/Study/StudyDetails?id=25563&tenant=MT_AST_9011

Link to plain language summary of the study on the Trial Results Summaries website

Other Identifiers

7163-CL-0107

Identifier Type: -

Identifier Source: org_study_id